

Nivolumab CheckMate025

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Nivolumab CheckMate025

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers  
Therapeutic Indication: As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults  
Experimental Arm: Nivolumab  
Control Arm: Everolimus



